Brought to you by 
Bayer exercises option on X-Chem epigenetic-targeting compound
29 Oct 2017
Executive Summary
Bayer HealthCare Pharmaceuticals AG exercised an option from X-Chem Inc. (small-molecule drug discovery) on an early-stage small molecule that inhibits an epigenetic protein. The partners began collaborating in a multi-target deal in July 2012, but only disclosed their alliance now.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer exercises option on X-Chem epigenetic-targeting compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice